Added to YB: 2024-02-09
Pitch date: 2024-02-09
ACRS [neutral]
Aclaris Therapeutics, Inc.
+162.1%
current return
Author Info
Clark Street Value is a special sits/event-driven investor. Sign up for the newsletter.
Company Info
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States.
Market Cap
$273.0M
Pitch Price
$1.24
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.66
P/E
-2.06
EV/Sales
6.86
Sector
Pharmaceuticals
Category
turnaround
Aclaris Therapeutics: Strategic Review for Broken Biotech, Big Discount to Cash
$ACRS strategic review after failed P2 trial. Cash ~$182M vs $85M mkt cap. Activists own 12%+, could push for sale like $RPHM. Risks: interim CEO may prefer cont'd dev vs sale. Trades well below cash but riskier biotech special sit.
Read full article (2 min)